The February 2027 FDA PCAC Peptide Review: What's Next After July

What is actually being decided

The 503A Bulks List determines which bulk substances a traditional compounding pharmacy may use to prepare a medication for an individual patient when no approved product fits. PCAC reviews nominated substances and recommends whether each belongs on that list. The committee does not approve drugs, does not set dosing, and does not decide what consumers may purchase.

Three separate things get conflated in community discussion, and keeping them apart makes this whole process easier to follow. Coming off the Category 2 list means FDA is no longer treating a substance as presumptively unsuitable for compounding. Being recommended for the 503A list means an advisory committee thinks it belongs there. Being an FDA-approved drug means a sponsor ran trials and the agency cleared a specific product for a specific indication. None of the twelve peptides in this process is in the third category, and a February recommendation would not put any of these five there either.

The five compounds under review

FDA has not yet published the briefing documents that will define the specific proposed use it evaluates for each compound. In July, those documents framed each peptide against a named indication, and the agency's assessment turned on whether human evidence existed for that use by the proposed route. Expect the same structure here. What follows is where each compound's published record stands going in.

GHK-Cu

The copper tripeptide has the deepest and most-replicated literature of the five, spanning wound healing, extracellular-matrix signaling, and dermatologic outcomes. It is also the one where the framing question matters most. The bulk of the persuasive human work is topical and cosmetic, an application where GHK-Cu has been used commercially for decades. Injectable systemic use, which is what the compounding conversation usually implies, has a far thinner evidence base. A committee could reasonably view the topical record as strong and the systemic record as unproven, and those two conclusions are not in conflict. See our GHK-Cu page.

LL-37

LL-37 is the human cathelicidin antimicrobial peptide, a real and well-studied component of innate immunity with a substantial academic literature on host defense, wound biology, and inflammation. The gap is translational: understanding a peptide's endogenous role is not the same as demonstrating that administering it produces a safe, reproducible clinical benefit. Its biology is also double-edged, with roles described in both antimicrobial defense and inflammatory pathology depending on context. See our LL-37 page.

Melanotan II

Of the five, this is the one carrying the most documented safety concerns. Melanotan II is a non-selective melanocortin agonist associated in the published literature and case reports with nausea, blood-pressure and cardiovascular effects, spontaneous erections, and changes in melanocytic naevi, with case reports of melanoma raising questions the field has not resolved. It also has a long grey-market history that predates this regulatory process. A favorable recommendation here would be the most surprising of the five, and the most consequential if it happened. See our Melanotan II page.

Dihexa acetate

Dihexa is an angiotensin IV analog developed in academic work around hepatocyte growth factor and c-Met signaling, with striking preclinical cognition data in rodent models. Human evidence is essentially absent. The community interest substantially outruns the published record, and the nootropic claims attached to it in marketing contexts are not supported by controlled human trials. See our Dihexa page.

PEG-MGF

PEG-MGF is a pegylated form of a peptide derived from the IGF-1Ec splice variant, popular in performance contexts on the theory that it extends the native mechano growth factor signal. Direct human evidence for the injected analog is minimal, the relationship between the marketed peptide and the endogenous splice variant is often overstated, and the compound sits in WADA-prohibited territory for competing athletes. See our PEG-MGF page.

What the July precedent does and does not tell us

On July 23-24, 2026 the committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A list, and declined only Emideltide (DSIP). FDA's staff reviewers had recommended against all seven. The full account is in our July 2026 PCAC review.

The useful signal is about the decision-maker rather than the science. Eight temporary members had been added to the panel before that meeting, and their votes supplied the margin on every compound that passed. Nothing in the underlying evidence changed between the briefing documents and the vote; the group weighing it did. If the February panel is constituted similarly, a staff recommendation against a compound is a weaker predictor of the outcome than it would have been a year ago.

The limits of that inference deserve equal weight. Every July vote was close, several by a single member. The one rejection shows the committee was willing to say no. And these five compounds are not the July seven: a panel inclined toward expanding compounding access could still balk at a compound with active safety signals in the literature, which is the specific issue Melanotan II presents. Treating July as a guarantee of a clean sweep in February would be reading more into it than the record supports.

What happens after a vote

This is where expectations most often go wrong. A PCAC recommendation is advisory. For any substance to actually join the 503A Bulks List, FDA must publish a proposed rule, take public comment, and issue a final rule — a sequence that realistically runs a year or more past the vote, and one the agency is not obliged to complete in the committee's favor. The six compounds recommended in July are still not compoundable on that basis today, and the same will be true the morning after the February meeting.

Even at the end of that road, a 503A listing means a licensed compounding pharmacy may prepare the substance against a valid prescription from a licensed prescriber. It does not make the compound an approved drug, does not validate any particular clinical claim, and does not legitimize purchase from research-chemical vendors, which operate outside this framework entirely.

What to watch between now and February

Three things will tell you most about how this round is likely to go, in rough order of usefulness:

• The briefing documents. When FDA publishes them, they will name the specific proposed use for each compound and lay out the agency's read of the evidence against it. In July these were the clearest available statement of the scientific case, even though the committee ultimately went the other way.
• The roster. Whether temporary members are again added, and how many, is the single most predictive detail available before the vote.
• The comment docket. FDA opens a public docket ahead of these meetings. It is the formal channel for clinicians, researchers, and the public to submit evidence and argument.

We will update this page when FDA posts the meeting date and the briefing materials, and again after the vote.

Where this nets out

The February 2027 meeting is the second half of a regulatory process that has already produced one surprising result. A committee that overrode its own agency's scientists on six of seven compounds is a different proposition from the one most observers expected, and that is a reasonable basis for expecting a friendlier reception for these five than the underlying evidence alone would predict.

It is not a basis for treating any of them as validated. The evidence gap that FDA's reviewers identified in July did not close because a vote went the other way, and for this group the gaps are wider in places — Dihexa and PEG-MGF have almost no human record, and Melanotan II has a safety literature that any serious review has to reckon with. The honest position going into February is that the regulatory odds have shifted while the science has not.